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Abstract 
Coma and disordered consciousness are common manifestations of acute neurological conditions and are among 
the most pervasive and challenging aspects of treatment in neurocritical care. Gaps exist in patient assessment, 
outcome prognostication, and treatment directed specifically at improving consciousness and cognitive recovery. In 
2019, the Neurocritical Care Society (NCS) launched the Curing Coma Campaign in order to address the “grand chal-
lenge” of improving the management of patients with coma and decreased consciousness. One of the first steps was 
to bring together a Scientific Advisory Council including coma scientists, neurointensivists, neurorehabilitationists, 
and implementation experts in order to address the current scientific landscape and begin to develop a framework 
on how to move forward. This manuscript describes the proceedings of the first Curing Coma Campaign Scientific 
Advisory Council meeting which occurred in conjunction with the NCS Annual Meeting in October 2019 in Vancou-
ver. Specifically, three major pillars were identified which should be considered: endotyping of coma and disorders of 
consciousness, biomarkers, and proof-of-concept clinical trials. Each is summarized with regard to current approach, 
benefits to the patient, family, and clinicians, and next steps. Integration of these three pillars will be essential to the 
success of the Curing Coma Campaign as will expanding the “curing coma community” to ensure broad participation 
of clinicians, scientists, and patient advocates with the goal of identifying and implementing treatments to funda-
mentally improve the outcome of patients.
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Coma is a clinical condition common across numer-
ous acute neurological disorders and non-neurologi-
cal disorders (such as drug overdose and decompen-
sated metabolic disease). Coma can herald long-lasting 
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2unconsciousness, a transient state followed by return of 
consciousness, or a chronic state characterized by partial 
recovery of consciousness [1–3]. The prognosis for return 
of consciousness is a critical determinant of family and 
medical care decisions regarding goals of care; whether 
to aggressively attempt to support patients or implement 
comfort measures (with the frequent outcome of death) 
[4, 5]. The most common and compelling issues faced by 
patients, families, and clinical care providers are whether 
a patient with impaired consciousness can ‘wake up’; 
if so, what level of awareness they can be expected to 
recover to, what the timeline for such a recovery may be, 
and what will it take to get there. Uncertainty in current 
methods of prognostication and the lack of pharmaco-
logical, surgical, and rehabilitation interventions that can 
specifically improve consciousness are the most encom-
passing challenges currently facing neurocritical care. In 
addition, concern regarding a self-fulfilling prophecy of 
poor outcome due to withdrawal of support in patients 
who might otherwise have a favorable outcome extends 
across acute neurological conditions, with traumatic 
brain injury as but one example [6]. Recognizing this gap 
in coma understanding and intervention, and the key 
importance of advancing research in this area, the Neu-
rocritical Care Society (NCS) has launched the Curing 
Coma Campaign [7].
By definition, coma defines a subset of patients with 
disorders of consciousness (DOC) and refers to a state 
of lack of arousal in which a brain injured patient has 
no interaction with his or her environment. DOC is 
a broader definition that encompasses patients with 
altered consciousness that may be less complete than 
coma. It should be emphasized that while clinical defini-
tions of states of disordered consciousness have recently 
been rigorously addressed (e.g., coma, vegetative state/
unresponsive wakefulness syndrome [VS/UWS], and 
minimally conscious state [MCS]), these constructs have 
been primarily implemented in the subacute and chronic 
phase of illness [3].
Acute coma and impaired consciousness have been tra-
ditionally studied and treated in a disorder-specific con-
text. For example, cardiac arrest, traumatic brain injury, 
and brainstem stroke are often considered separately 
with regard to prognosis, intervention and rehabilitation 
strategies. However, the minimum common-denomi-
nator anatomy and physiology of altered consciousness 
across diseases might be more relevant when consider-
ing targeted interventions to improve patients with DOC 
[8–11]. Advancing knowledge about the pathogenesis 
of altered consciousness has potential to generate fun-
damental revelations that can be used to develop treat-
ments for patients with a broad range of DOC etiologies 
[12–15].
The Curing Coma Campaign aims to “change the game” 
by moving beyond the limitations imposed by consider-
ing a specific phase of illness such as subacute/chronic or 
disorder-specific investigation in order to cover the entire 
disease narrative, from ictus to outcome, and articulate a 
comprehensive and rational clinical taxonomy of severe 
DOC. The campaign also aims to go beyond a simple 
descriptive exercise and use this classification as a basis 
to dissect mechanisms, improve prognostication, iden-
tify test therapies, and impact outcomes. Perhaps most 
importantly, we wish to use this campaign as a means of 
bridging the presentation of coma in the acute phase to 
its eventual outcome. This will necessitate engagement 
with clinicians in post-acute care, since a continuum 
approach provides the best chance of making meaning-
ful changes that affect the lives of our patients. By bridg-
ing current consciousness science with new research 
regarding patients with DOC across a broad array of 
initial causes, the intent is to develop an enduring frame-
work for studying, promoting awareness, and developing 
treatments. Furthermore, as neurocritical care expands 
worldwide, it is a priority to identify ways to improve care 
that can be implemented across differently resourced 
environments [16, 17].
With its launch in 2019, one of the first efforts of the 
Curing Coma Campaign was to bring together a diverse 
group of coma scientists, neurointensivists, neuroreha-
bilitationists, and implementation experts into a Scien-
tific Advisory Council (SAC). The initial task of the SAC 
was to identify scientific gaps in order to facilitate the 
development of a scientific “roadmap.” The Curing Coma 
Campaign SAC met for the first time in person during 
the NCS Annual Meeting in Vancouver in October 2019. 
This manuscript describes the overall proceedings of that 
first meeting, addressing three fundamental and over-
arching pillars to lay the foundation for next steps. These 
pillars are (1) Endotyping—developing a better under-
standing of the different types of coma, (2) Biomark-
ers—evaluating current tools and their shortcomings in 
understanding coma and its prognosis, and (3) Proof-
of-Concept Clinical Trials—identifying early proof-of-
concept interventional studies to evaluate new treatment 
protocols and inform clinical trial design. Three separate 
groups were tasked with describing the background, cur-
rent understanding, and impact for patients and families 
for each pillar. In addition, they were asked to summarize 
the integral problems and to propose next steps. Princi-
ples were then reviewed, discussed, and revised by the 
entire SAC.
Endotyping
This pillar was initially considered as “phenotyping” of 
DOC. However, the term “phenotype” was recognized 
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primarily as evidenced by the neurological examination. 
The fact that different disease entities and structural or 
metabolic mechanisms can result in similar ‘clinical phe-
notypes’ was identified as one of the reasons for current 
limitations in coma assessment and treatment. Thus, 
this pillar was changed to endotyping to more accurately 
reflect the gap and challenge faced. To date, DOC endo-
types in the acute stage have not been well classified. A 
better identification of DOC endotypes and their recov-
ery trajectories early in the course of intensive care unit 
(ICU) management may delineate patients with a high 
chance of recovery and distinguish those who may be 
amenable to specific interventions from those with a 
poor likelihood of recovery.
Current Approach in DOC Classification and Clinical 
Recovery Trajectories
Clinicians are regularly confronted with the difficult 
challenges of assessing the cause of coma, prognosis for 
recovery, and expected trajectory of recovery. Clinical 
assessment typically relies on the observed behavior of 
the patient and results from clinical examination testing. 
However, clinical examination may be insensitive for the 
detection of recovery of consciousness and other cog-
nitive functions, which may only be captured by novel 
methods such as advanced neuroimaging or electro-
graphic studies. So far, no coma assessment battery exists 
that can properly and definitively endotype DOC in the 
ICU. This leads to uncertainty regarding prognosis and 
trajectory of recovery, as well as increasing the potential 
for misclassification. The assessment of coma, and related 
states such as UWS and MCS, is limited due to patient-
specific factors, inconsistent interrater reliability in the 
clinical exam, and factors that may confound clinical 
assessment such as intubation and sedation [18]. Recent 
guidelines pertaining to DOC, focused on subacute and 
chronic patients, have assessed the current state of evi-
dence and provided a framework for addressing gaps [19, 
20].
Current prognostic models are deficient with regard to 
the time window and degree of expected recovery. Arbi-
trary time points for outcome assessment that may have 
been chosen for pragmatic reasons often fail to capture 
functional recovery. For example, assessment at 3 months 
may not capture ongoing recovery that can continue for 
1 year after injury and beyond, even in patients who do 
not regain full consciousness in the ICU [21].
Individual patients with different trajectories are 
commonly lumped together, providing an incomplete 
view of heterogeneous recovery patterns that may be 
related to nuanced anatomic or functional circuitry 
impairment. Additionally, widespread subcellular 
functional alterations may endure for long periods of 
time producing sustained coma in brains harboring a 
potential for good outcomes [22]. The ultimate goal is 
to endotype DOC in order to achieve precision diag-
nosis for the cause and recovery trajectory. This would 
allow clinically and biologically relevant subgroups to 
be parsed for improved prognostication and targeted 
interventions.
Proposed Classification of Different Coma Endotypes 
and Recovery Trajectories
An initial classification of DOC endotypes could focus 
on how the specific coma/DOC mechanism is linked 
to recovery and potential interventions. Four different 
general subgroups emerge:
1. DOC endotype without commensurate structural 
damage In principle, these could be reversible using 
traditional treatment approaches (e.g., seizures, drug 
overdose) and are recognized based on metabolic or 
electrical instability.
2. DOC endotype with structural or functional damage 
that is amenable to replacement or bypass therapy 
This would include damage that could potentially be 
replaced by surrogate brain function such as stimu-
lant medications or brain-machine interfaces [12, 
23]. Even if interventions are not present today, this 
endotype would represent a high-priority and fertile 
target for identifying and testing new interventions. 
Except in the most severe cases, hypoxic-ischemic 
injury and traumatic brain injury would fit in this cat-
egory.
3. DOC endotype that is not amenable to pharmacologic 
or anatomic replacement or repair therapy Essen-
tially, this would be untreatable conditions based on 
the underlying biology, such as end-stage prion or 
Alzheimer disease. This endotype may progress from 
endotype 1 or 2 when metabolic, electrical, or struc-
tural disease is not reversed. It would be hoped that 
this endotype might be a “moving target” in which 
novel therapies emerge that can arrest disease pro-
gression and move patients into endotype 1 or 2 by 
virtue of more successful therapies to reverse meta-
bolic or electrical instability or provide replacement 
or bypass therapy.
4. DOC mimics endotype in which structural damage 
results in a syndrome that mimics or is mistaken for a 
DOC. Examples could include severe aphasia, abulia, 
or locked-in syndrome. Such endotyping could allow 
targeted treatment for these alternate impairments 
with similarly profound functional impact.
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Multimodal tools exist to endotype coma and DOC [19, 
24]. Neuroimaging methods such as magnetic reso-
nance imaging (MRI) (e.g., resting state functional MRI, 
task-based functional MRI, and diffusion tensor imaging 
[DTI]) and positron emission tomography (PET) (e.g., 
resting state PET) have been used to identify patients 
with preserved neural networks (MRI/DTI and PET) and 
covert consciousness (task-based fMRI) [25, 26]. At pre-
sent, it is not clear which brain circuits are required to 
regain consciousness and what morphological changes 
translate to clinical trajectories. Likewise, electrophysi-
ologic methods (electroencephalography [EEG], high-
density EEG [hdEEG], transcranial magnetic stimulation 
EEG [TMS-EEG]) enable refined evaluation of conscious-
ness and higher-order cortical function [27–29]. Func-
tional networks in the brain at rest are associated with 
the state of consciousness in DOC [30]. Specifically, rest-
ing default mode network connectivity may be an impor-
tant concept to characterize the state of consciousness 
underpinned by electrophysiologic networks [31, 32]. 
Electrographic studies may be combined with active and 
passive perturbation tasks to further elucidate different 
endotypes of coma. Other invasive monitoring methods 
also provide assessment of the brain physiological state, 
oxidative substrate delivery (e.g., brain tissue oxygena-
tion, regional cerebral blood flow [rCBF], intracranial 
pressure [ICP], cerebral microdialysis, brain water, brain 
temperature, spreading depolarizations), and serum and 
cerebrospinal fluid (CSF) metabolic biomarkers.
Benefits to the Patient, Family, and Clinicians
Early recognition of different endotypes of coma may 
identify patients with various recovery trajectories early 
in the ICU setting, leading to improvement in the accu-
racy of early neuro-prognostication. Identification of 
patients amenable to interventions at specific time points 
will enable clinical trials of targeted treatments to accel-
erate emergence from coma and improve cognitive and 
functional outcome. A valid trajectory model would facil-
itate communication between the patient, family mem-
bers, and clinicians.
Next Steps in Endotyping Coma and Redefinition 
of Recovery Trajectories
Three next steps are suggested. First, there is a need to 
develop clinically and biologically relevant coma endo-
types. Second, it is important to identify one or more 
endotypes amenable to treatment. Third, development 
of well-defined common data elements (CDE) for DOC 
and its recovery trajectory are necessary to standardize 
future work. This approach has the potential to dramati-
cally advance care of comatose neurocritical care patients 
through identification of relevant coma endotypes early 
in the ICU and relating these endotypes to various trajec-
tories, with the ultimate goal of applying individualized 
treatment strategies based on clinically and biologically 
stratified coma endotypes.
Biomarkers
In today’s ICU, patients can be monitored with a suite of 
tools that includes physiological signals, imaging, fluid 
chemistries, neuro-electrical stimulus response, and cli-
nician observations. While findings from these tools 
(biomarkers) provide a degree of information on the 
patient’s state, they remain insufficient to identify details 
of the endotype of comatose patients, cause of the coma, 
or severity of the disease, all of which are necessary to 
provide the most effective treatment and to identify new 
targeted interventions.
Additionally, as treatment is given, it is important 
that a patient’s disease state be accurately monitored to 
determine if the course of treatment should be modified. 
This will require data synchronization and integration 
though clinical informatics. While recovery trajectories 
have been identified following emergence from coma, 
there is a critical need to define coma recovery trajecto-
ries during the acute period [33]. Tools to follow patients 
throughout the course of disease are critically important 
to define coma recovery trajectories. Development of 
multidimensional flexible trajectory models that inte-
grate clinical, neuroimaging, electrographic, and other 
biomarker data at different time points is a high priority. 
In addition, standardized approaches to clinical assess-
ment, imaging, or other testing and adjusting for thera-
peutic interventions will be needed to develop validity for 
trajectory models.
Current Biomarker Uses in Comatose Patients
While a range of tools to find biomarkers already exist, 
many are difficult to administer to comatose patients 
or do not provide the accuracy and precision necessary 
to pinpoint location (and severity) of the lesion or con-
nectivity of integrated networks. As a result, there is a 
need for biomarker tests that are suitable for use in the 
ICU setting. Consciousness is a state that is elusive and 
not necessarily directly measurable. In the clinical con-
text, assessing the presence of consciousness in a patient 
is based on pragmatic principles in which a patient can 
demonstrate voluntary/purposeful behaviors that can be 
taken to imply a state of (at least minimal) consciousness. 
When categorizing biomarkers, however, both the physi-
ological signal that is measured as well as the context in 
which the signal is obtained (e.g., assessment at rest ver-
sus during a task) need to be clearly specified in order to 
evaluate the degree to which each biomarker is associated 
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because there are fluctuations in the patient’s physical 
and neurological examination that relate to lesion locus, 
sleep–wake cycles, medication administration, and 
comorbidities such as infection and systemic organ dys-
function that may confound clear interpretation.
The three goals of biomarkers in patients with coma 
and DOC are to (1) make endotypic or mechanistic diag-
nostic determinations (see the section above), (2) to fol-
low the progression of the comatose patient, either as 
natural history or in the context of an intervention, and 
(3) to develop multidimensional flexible trajectory mod-
els for comatose ICU patients using neuroimaging, elec-
trophysiology and other biomarkers. The ideal biomarker 
in each situation is distinctly different. As described in 
the preceding section, for endotypic biomarkers, ideal 
tests need to have high sensitivity and specificity. Com-
plexity of interpretation is probably a less important hur-
dle because the tests will likely be administered once. 
For following disease progression and trajectory of recov-
ery, repeated measurements that are easy to interpret in 
real time are preferable to complex tests. For develop-
ing models, integration of complex and readily repeated 
measures will be necessary.
Another way to categorize biomarkers is to separate 
mechanistic markers that inform the underlying pathol-
ogy from outcome markers that predict which patients 
will improve. This dichotomy may be useful to select 
biomarkers for use in different situations. For example, 
a mechanistic marker may be important in developing a 
clinical trial of an intervention but may be less useful to 
inform families about the patient’s prognosis. While an 
outcome marker may be useful in exactly the opposite 
circumstance.
There are specific unmet needs that will guide new bio-
marker development. First, unlike endotyping biomark-
ers that are rapidly advancing, biomarkers that identify 
and monitor progression of specific dysfunctional brain 
circuits are currently not available but would be of great 
value. Second, there is an unmet need for biomarkers that 
indicate real-time progression of brain injury. Successful 
evaluation of the natural history of disease and treatment 
response in early phases of injury depends on clear dis-
crimination of transient versus permanent brain injury.
Finally, there is an early, persuasive case for exploring 
genetic variations that could drive the likelihood of pro-
longed DOC after an acute insult or affect the likelihood 
of recovery. While the likelihood of prolonged DOC has 
been addressed in genetic association studies (such as 
in TBI), direct extension to the specific outcome of poor 
emergence is difficult [34]. Genetic drivers of recovery 
trajectories are less well studied. However, it is biologi-
cally plausible to consider whether emergence from DOC 
could be influenced by genes responsible for cognitive 
reserve, sleep, inflammatory host response, late neurode-
generation, and neural regeneration and repair. Genetic 
markers could prove important for several reasons. Such 
variations may stratify patients in terms of risks of non-
emergence—which is particularly important considering 
some patients may achieve late (and often unexpected) 
recoveries. Second, genetic biomarkers may allow us 
to identify new biological targets and develop new 
therapies.
Approach to Solving the Problem—the Ideal Biomarker 
for Coma in the ICU
No biomarker today has the ability to clearly map the 
function of thalamocortical interactions or the reticu-
lar activating system, both of which are critical for con-
sciousness. Table  1 provides a description of currently 
used biomarkers to assess and quantify consciousness. 
When considering biomarkers of consciousness, it is 
useful to assess them along the axes of biological signal 
and context. Biological signals assessed at rest quantify 
brain physiology that is necessary to maintain a con-
scious state. Passive perturbation tests measure biologi-
cal signals (biomarkers) in response to external sensory 
or direct neuronal stimuli. The recorded signal allows an 
assessment of brain activation associated with stimula-
tion, thereby providing a correlate to level of conscious-
ness. Active perturbation tasks confront the patient with 
a task and measure the response. The most widely used 
behavioral assessments for consciousness in the clinical 
context evaluate eye opening, visual fixation and pur-
suit, and motor responses to command or stimulation. 
The current practice standard for behavioral assessment 
of consciousness is the Coma Recovery Scale Revised, 
which is superior to other clinical scales [35]. This assess-
ment allows clinical classification into coma, VS/UWS, 
MCS (minus and plus), and emergence from MCS. 
Patients who demonstrate volitional responses during 
task-based EEG or functional MRI but who are unable to 
follow commands on behavioral assessment are labeled 
as having covert consciousness, or cognitive motor dis-
sociation [36].
When prioritizing tests of biomarkers, accuracy of 
measurement (scientific yield) and availability in the ICU 
(applicability) need to be considered. Ideally, these tools 
would be available at the patient’s bedside and could be 
performed repeatedly (or automated). Currently, the 
highest yield and broadly available tests are behavioral 
assessments and resting EEG, which additionally eluci-
date biomarkers of reversible coma endotypes including 
seizures (endotype 1). It is crucial that the behavioral 
assessment is standardized, and this requires training of 
examiners. With additional standardized computational 
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ate immediately available useful measures of conscious-
ness. Particularly the ABCD model is a promising resting 
EEG tool as it provides a hierarchical representation of 
the degree of thalamocortical disconnection [37]. Active 
paradigms in which the patient is asked to respond 
to command while monitored with EEG and passive 
approaches such as the “local–global violation” para-
digms, which have been closely linked to the presence 
of consciousness, as well as  specific markers computed 
from resting state  analysis  EEG are feasible to assess in 
an ICU setting and associated with good long-term func-
tional outcomes [28, 38, 39]. However, utilization of these 
approaches requires replication, standardization, and 
computational resources [28]. Similarly, diffusion tensor 
imaging and resting state MRI provide an assessment of 
underlying structural and functional connectivity of the 
brain, respectively [40–42]. Like all imaging measures, 
these require transport of the patient out of the critical 
care setting and provide assessment at a limited number 
of time points. Much of the brain physiology, structural 
imaging, and injury measures are correlated with extent 
of impairment of consciousness and provide insight into 
underlying mechanisms but are low yield as biomarkers 
for consciousness. However, it should also be noted that 
the post-processing of neuroimaging data requires exten-
sive expertise and constant monitoring of best practices 
given its sensitivity to very small noise sources as well as 
the theoretical and empirical limitations of applying to 
severe brain injury patients processing and analytic algo-
rithms that were developed for healthy volunteers [43, 
44]. As research progresses, applicability and availability 
of any biomarker for the ICU context may change and 
guidance should be given as to which measures are high-
est yield if made broadly available. Functional MRI with 
motor imagery, PET, and transcranial magnetic stimula-
tion with EEG co-registration offer particular scientific 
promise, but possess numerous challenges related to fea-
sibility in real-world ICU settings.
Benefits to the Patient, Family, and Clinicians
There are three distinct ways that biomarkers will ben-
efit. For families, better and more accurate information is 
important. For clinicians, following progression of DOC 
in response to medications will give insight into the util-
ity of the treatment. For researchers, correlating both 
better endotypic definition of DOC and disease progress 
over time with the site and magnitude of injury will be 
critical to make inferences about pathophysiology.
New biomarkers that accurately determine DOC 
endotypes could be used to guide patient treatments 
toward improved cognitive and functional outcomes. 
Families will receive more precise prognostic infor-
mation and clinicians will better monitor patient 
trajectories in order to modify treatments. As has 
been mentioned previously, early withdrawal of life 
Table 1 Currently used biomarkers for the assessment of consciousness
BAEP brainstem auditory evoked potential, CPP cerebral perfusion pressure, CT computed tomography, CTP computed tomographic perfusion, EEG 
electroencephalography, ERP event-related potential, FDG PET fluorodeoxyglucose positron emission tomography, FLAIR fluid-attenuated inversion recovery,  FOUR  
full outline of unresponsiveness, GFAP glial fibrillary acidic protein, ICP intracranial pressure, MEP motor evoked potential, MR magnetic resonance, MRI magnetic 
resonance imaging, NSE neuron specific enolase, rCBF regional cerebral blood flow,SSEP somatosensory evoked potential
Brain at rest
Structural assessment: brain MRI (FLAIR, high resolution T1, diffusion tensor imaging), Head CT
Neuronal activity: spectral analysis (ABCD classification), permutation entropy and spectral complexity and connectivity measures of the resting EEG
Functional connectivity: EEG coherence, phase-amplitude modulations, resting state functional MRI
Direct measures of brain physiology: metabolism (FDG PET), oxygen (partial brain tissue oxygenation and oxygen saturation), blood flow (MR or CT 
perfusion imaging, MR arterial spin labeling, Xenon CTP, invasive measure of rCBF), ICP/CPP, cerebral metabolites (MR spectroscopy, microdialysis), 
brain water content, brain temperature, cortical spreading depolarization
Measures reflecting injury to the brain: CSF and serum (NSE, S110Beta, GFAP, vimentin, myelin basic protein, inflammatory markers such as IgG electro-
phoresis)
Passive perturbation tasks
Sensory stimulation induced evoked potentials (SSEP, BAEP, MEP): short vs long latency
Event-related potentials: cognitive processing involved with processing of regularities (i.e., local global paradigm), processing of ERPs induced modula-
tion of the autonomic nervous system
Transcranial magnetic stimulation with high-density EEG co-registration
Stimulus-based functional EEG or functional MRI (e.g., with language or music stimuli)
Active perturbation tasks
Behavioral assessment: coma recovery scale-revised, other less comprehensive clinical scales (FOUR score, Glasgow Coma Score), differential electro-
myographic response
Task-based functional EEG or functional MRI (e.g., commanded motor acts, motor imagery, or spatial navigation)
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in patients with DOC. Better information will improve 
the shared decision making between caretakers and 
families [6].
For development of treatment strategies, biomarkers 
will be critical to determine whether treatments make 
a difference. It is quite possible that hurdles in measur-
ing improvement (or lack thereof ) in DOC studies may 
represent the most important hurdle to finding therapies. 
It is possible that existing medications are useful in the 
treatment of patients with DOC, but the correct dose 
and timing is obscured by the inability to detect early 
improvement.
In the study of patients with DOC, biomarker develop-
ment will also have an important role. Because human 
research limits the output variables available to correlate 
with pathology, improvements in biomarkers will allow 
researchers to make inferences about which pathology or 
network dysfunction is remediable.
Next Steps to Biomarker Development
Given the plethora of existing potential biomarkers 
and the lack of clarity regarding actionable information 
for predicting and tracking recovery of consciousness 
in acutely injured patients, a two-pronged approach is 
needed. First, the most relevant anatomic and biochemi-
cal pathways should be identified that indicate the ability 
to emerge from coma and improve cognition. Prospective 
studies of highly characterized endotypes with clinical 
correlation and other candidate biomarkers will need to 
be undertaken. Early assessment at the time of injury and 
over a period of years will be necessary. Preliminary find-
ings from these studies will drive sample size estimates 
to inform the breadth and scope ultimately needed for 
further study. In addition, changes in biomarker values 
with current clinical interventions and the relationship to 
coma recovery will refine mechanistic pathways.
To study the underpinnings of DOC, a mechanistic 
approach will suggest specific types of biomarkers that 
interrogate these pathways. Certain biomarkers that pro-
vide information regarding brain injury or outcome pre-
diction but do not link directly to mechanistic pathways 
can be rejected as tangential to the primary project focus, 
while other biomarkers not yet in existence may need to 
be developed. Second, it is important to coalesce existing 
biomarker experience regarding neuroimaging, electro-
physiology, serum and CSF studies, and physiology into a 
shared accessible dataset that allows cross-referencing of 
patients for exploration of mechanistic insights that may 
feed back into the first prong. Existing data, while dispa-
rate, is a powerful tool to utilize if regulatory, data shar-
ing, and incentive issues can be worked out.
Proof‑of‑Concept Clinical Trials to Promote 
Recovery of Consciousness in the ICU
ICU clinicians currently lack treatments proven to pro-
mote early recovery of consciousness during the first 
28 days post-injury. Without knowing whether a patient 
can or will recover consciousness, families may withdraw 
life-sustaining therapy. This decision accounts for up to 
70% of deaths in patients with DOC following TBI and 
over 40% of deaths in comatose patients with hypoxic-
ischemic injury [5, 45].
To date, clinical trials of consciousness-promoting 
therapies in patients with DOC resulting from a struc-
tural cause have been performed almost entirely in the 
subacute-to-chronic stage of recovery [46]. The focus 
on late-stage interventions has likely resulted in missed 
early-intervention opportunities for restoring conscious-
ness. Prior proof-of-concept trials have tested pharma-
cologic and electrophysiologic therapies for their effect 
on arousal and awareness (the two essential compo-
nents of consciousness). Most pharmacologic trials have 
tested stimulant medications, particularly those that 
promote dopamine signaling within the brain, including 
amantadine [47], methylphenidate [12], levodopa [48, 
49], bromocriptine [50], pramipexole [50], and apomor-
phine [51]. Zolpidem, a sleep aid, has also been tested 
in patients with subacute-to-chronic DOC because of 
its paradoxical awakening effect in a small subset of 
patients, which is hypothesized to be related to a change 
in background activity levels of thalamocortical circuits 
(mesocircuit) [52, 53]. Electrophysiological trials have 
tested deep brain stimulation [13], transcranial mag-
netic stimulation [54], transcranial direct current stimu-
lation [15], low intensity focused ultrasound pulsation 
[55], and vagal nerve stimulation [56]. Yet, despite initial 
encouraging results from several proof-of-concept phar-
macologic and electrophysiologic trials conducted in the 
subacute-to-chronic setting, there have been few stud-
ies of consciousness-promoting therapies in the acute 
ICU setting. In one example, an electroclinical response 
to a time-limited trial of an anti-seizure medication has 
been advanced as part of the criteria to diagnose indeter-
minate epileptiform activity constituting “probable non-
convulsive status epilepticus” (although a standardized 
approach to codifying an electroclinical response has yet 
to be validated) [57]. Regardless of etiology, the Curing 
Coma Campaign aims to advance the design and imple-
mentation of rigorous, proof-of-concept clinical trials in 
the ICU, with the ultimate goal of providing conscious-
ness-promoting therapies to patients with acute DOC.
Current State of Clinical Trial Development
Two major barriers have prevented the development of 
consciousness recovery therapy in the ICU: (1) patients 
8are not rigorously endotyped prior to enrollment in clini-
cal trials, and (2) therapeutic responses are not tested 
with appropriate measures of brain function in early-
phase clinical trials. Instead of enrolling patients based 
on the pathophysiologic mechanism of coma, trials often 
enroll patients based on a behavioral measure such as 
the Glasgow Coma Scale (GCS) score or the Full Outline 
of UnResponsiveness (FOUR) Score, which grade brain 
injury on a continuum from mild to severe and focus on 
initial clinical severity rather than pathophysiology and 
trajectory [58, 59]. This approach is ineffective because 
coma is a highly heterogeneous and dynamic condition. 
Traumatic and hypoxic-ischemic coma, for example, are 
associated with variable combinations of axonal discon-
nections within brain networks essential for conscious-
ness [60, 61]. Early-phase trials have also historically 
relied upon indirect serologic markers of brain injury or 
insensitive measures of disability [62]. Without biomark-
ers that directly measure brain function, fundamental 
questions about a therapy’s mechanisms of action can-
not be answered in early-phase trials. These barriers have 
contributed to the 0% success rate for Phase 3 clinical tri-
als conducted in patients with coma in the ICU. It is clear 
that a new, mechanistic approach to clinical trial design is 
needed [14, 62, 63].
Approach to Solving the Problem
When designing new trials to promote recovery of con-
sciousness in the ICU, two questions will need to be 
answered: (1) which substrates of consciousness are pre-
served, and (2) does the new therapy either engage these 
targets directly to restore consciousness or alternatively 
reverse an underlying illness temporarily disabling these 
targets? New tools are required to answer these ques-
tions. Specifically, tools are needed that identify pre-
served brain network connections in critically ill patients. 
Over the past decade, there have been rapid advances in 
the ability to map human brain networks that are essen-
tial for consciousness. These consciousness-supporting 
networks include the subcortical ascending arousal net-
work, or reticular activating system, and cortical default 
mode network, both of which have recently been mapped 
in ICU patients with acute brain injuries [41, 61, 64]. 
There is an urgent need to develop network mapping 
techniques that can provide repeated bedside assess-
ments during the acute phase in the ICU.
Early clinical trials may focus on biomarker validation 
and development in addition to intervention. The Cur-
ing Coma Campaign will support a multimodal approach 
in which a broad range of potential predictive biomark-
ers and pharmacodynamic biomarkers are tested in 
early-phase clinical trials. This approach has already 
demonstrated utility in predicting 6-month outcome in a 
cohort of patients with TBI [65].
Benefits to the Patient, Family, and Clinicians
The clinical motivation for development of conscious-
ness-promoting therapies in the ICU is that early recov-
ery of consciousness could reduce the likelihood of 
premature withdrawal of life-sustaining therapy, facilitate 
self-expression, and increase access to rehabilitative care 
to accelerate the trajectory of recovery. Early recovery of 
consciousness will also decrease the risk of ICU-related 
complications (e.g., infection and deep vein thrombosis) 
that lead to higher morbidity and mortality rates.
Next Steps to Developing Proof‑of‑Concept Clinical Trials
With recent studies showing that pharmacologic and 
electrophysiologic stimulation therapies can reactivate 
brain networks in selected patients, personalized con-
nectome mapping tools and fluid biomarkers available at 
the point-of-care are urgently needed to identify patients 
who may benefit from these therapies. We envision that 
a principled, mechanistic approach to predicting and 
measuring responses to new therapies in the ICU could 
allow clinicians to provide targeted treatments that are 
personalized to each patient, ensuring that each patient is 
given the best possible chance to recover consciousness 
in the ICU and beyond.
To our knowledge, there are two ongoing or soon-to-
be-launched clinical trials that incorporate the princi-
ples outlined above to engage targets in consciousness 
networks directly: Low Intensity Focus Ultrasound Pul-
sation (LIFUP; ClinicalTrials.gov NCT02522429), and 
Stimulant Therapy Targeted to Individualized Connec-
tivity Maps to Promote ReACT ivation of Consciousness 
(STIMPACT; ClinicalTrials.gov NCT03814356). Each 
trial aims to stimulate a preserved pathway within the 
connectome (the “wiring diagram” of the brain), though 
diagnostic tools to identify these pathways are still being 
refined and developed. With the support of the Curing 
Coma Campaign, these clinical trial efforts will leverage 
the expertise and experience of the neurocritical care and 
consciousness science communities.
Conclusions
The “grand challenge” of Curing Coma is ambitious and 
could be seen by some as diffuse or unattainable. How-
ever, the issues faced by patients and the current gaps 
in prognostication and intervention necessitate that the 
multidisciplinary field of coma science and recovery 
come together and take a fresh, bold, and substantive 
new approach. The Curing Coma SAC and these initial 
proceedings describe three foundational pillars that rep-
resent a first step. Undoubtedly, this will require a large 
9coordinated effort, for which analogies to the “moon-
shot” of the 1960s United States space program are inspi-
rational [66, 67]. One of the additional conclusions of the 
SAC meeting is that its current membership, while useful 
to initiate the Curing Coma Campaign scientific agenda, 
has knowledge gaps that will necessitate contributions 
from many more members of the scientific, clinical, edu-
cation, and implementation community. Thus, these pro-
ceedings should be seen as setting an initial framework 
whereby others can join, contribute, and drive the mis-
sion forward.
One interesting result of this review derives from 
common aspects identified across the three pillars and 
the intersection of the three toward the common goal 
of improving care of patients with coma and DOC. All 
three groups concluded that biomarkers that allow the 
correct identification and track progress of patients 
with impaired consciousness are critical to move the 
field forward. The biomarkers group further identified a 
number of different types of biomarkers including behav-
ioral assessments, blood tests, physiological tests (such as 
EEG), and imaging tests that have relevance. In addition, 
while it may be acceptable to have complex tests used at 
the beginning of therapy to make initial endotypic diag-
noses, tests that inform the ongoing progress of patients 
need to be interpretable at bedside. Further, biomarkers 
can be leveraged in different patient situations to make 
them more useful. For example, both resting EEG and 
passive and active perturbation tests can illicit more 
information about brain responses than either test alone.
Another important conclusion relates to the need for 
a rational system for endotyping patients with altered 
consciousness. Although many potential systems are pos-
sible, one based on the potential for treatment success 
may be the most rational. One construct could involve 
four basic endotypic categories: DOC endotype (1) 
without structural damage, (2) with structural damage 
that is amenable to replacement or bypass therapy, (3) 
with structural damage that is not amenable to replace-
ment or bypass therapy, and (4) coma mimic endotype. 
A pragmatic approach such as this would focus attention 
on rapid identification of distinct trajectories of recovery 
which will inform more targeted treatment interventions. 
Furthermore, as new interventions become available, 
specific mechanisms of DOC may move across DOC 
endotypes (e.g., a previously untreatable type of coma 
becomes treatable).
Finally, the group charged with identifying real world 
strategies to test therapies concluded that the lack of 
appropriate biomarkers and limitations in endotyping 
individual patients make interventional trials difficult 
to construct and interpret. The development of com-
mon data elements for DOC is important for endotyping 
coma patients in the ICU and will be critical to the suc-
cess of future clinical trials and biomarker development 
[68].
All of the groups identified specific barriers to study-
ing patients with coma and impaired consciousness. A 
major barrier is that the specific nervous system circuits 
that gate consciousness are not fully understood and are 
difficult to image or test in real time, especially in acutely 
critically ill patients. Most current biomarkers and endo-
types use the measurable, but imprecise, surrogate of 
whole-brain-impairment to make assessments about 
hard-to-measure specific consciousness circuit integ-
rity. In the future, the ability to specifically investigate 
and target consciousness circuits will be a necessity. All 
three groups also identified the dearth of studies assess-
ing complex mechanisms of consciousness impairment 
in the acute setting. Technological barriers to current 
biomarker use, especially imaging, in acute critically ill 
patients will need to be overcome. To date, most clinical 
trials focusing specifically on improving consciousness 
in impaired patients have been performed in the suba-
cute and chronic settings. It may be that biomarkers and 
endotypes that are useful in later stages of illness may not 
be appropriate in the acute setting.
It is important to note that the challenges outlined in 
this paper focus on human investigations. The nature and 
complexity of consciousness makes it difficult to model 
in non-human animals. The limitations on mechanistic 
inferences in human clinical trials make it vitally impor-
tant that researchers continue to develop non-human 
models that can test mechanistic aspects of conscious-
ness and DOC. There is a critical need for animal and in 
silico models of brain activity that can be interrogated to 
investigate specific aspects of consciousness recovery. 
There is already a robust field of animal consciousness 
research that is beyond the scope of this document and is 
reviewed elsewhere [69].
In summary, these proceedings represent a first step 
toward framing the broad scientific challenges likely to be 
faced by the Curing Coma Campaign as it seeks to fun-
damentally improve the understanding and treatment of 
acute DOC. Reporting plans and progress as they unfold 
will be important in order to bring together the “curing 
coma community” across science, advocacy, education, 
and implementation. The NCS invites comments and col-
laboration as the Curing Coma Campaign proceeds and 
develops with the goal of awakening hope and improving 
the care of these most vulnerable patients.
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